GlaxoSmithKline reorganisation continues

Japanese food and beverage firm Suntory is well on the way to acquiring both the Ribena and Lucozade brands from GlaxoSmithKline.

For some time, the global healthcare company has been working on restructuring its business, and speculation that this would involve asset-stripping has been well documented. The latest turn of events is unlikely to surprise the markets, and the anticipated value of around £1 billion will no doubt be well regarded. With Suntory Beverages having stated that it is willing to spend up to £3.25 billion on various takeovers this year, this deal looks to stand a very good chance of going through to completion.

The markets have been somewhat uninspired by the developments in GlaxoSmithKline of late, and this has resulted in the shares drifting below the 50- and 100-day moving averages over the last week’s trading. Admittedly the general sentiment of the equity markets has been somewhat muted over the last month, but even taking that into consideration the markets will be looking for the firm to follow through on its restructuring talk. Nevertheless, IG clients have been staunch in their support of the 4.6% dividend-yielding company, as they are 94% long.

GlaxoSmithKline plc chart

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.